1060 related articles for article (PubMed ID: 17386122)
41. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
Torrisi R; Bagnardi V; Rotmensz N; Scarano E; Iorfida M; Veronesi P; Luini A; Viale G; Santoro A; Colleoni M; Goldhirsch A
Breast Cancer Res Treat; 2011 Apr; 126(2):431-41. PubMed ID: 21221766
[TBL] [Abstract][Full Text] [Related]
42. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
[TBL] [Abstract][Full Text] [Related]
43. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
[TBL] [Abstract][Full Text] [Related]
44. Current and future status of adjuvant therapy for breast cancer.
Coleman RE
Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
[TBL] [Abstract][Full Text] [Related]
45. Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility.
Franco JG; Oliveira JB; Petersen CG; Mauri AL; Baruffi R; Cavagna M
Med Hypotheses; 2012 Apr; 78(4):442-5. PubMed ID: 22284634
[TBL] [Abstract][Full Text] [Related]
46. Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer.
Briest S; Wolff AC
Expert Rev Anticancer Ther; 2007 Sep; 7(9):1243-53. PubMed ID: 17892424
[TBL] [Abstract][Full Text] [Related]
47. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
Pan K; Chlebowski RT
Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
[TBL] [Abstract][Full Text] [Related]
48. Goserelin (Zoladex)--its role in early breast cancer in pre- and perimenopausal women.
Jonat W
Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):1-5. PubMed ID: 11900209
[TBL] [Abstract][Full Text] [Related]
49. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial.
Sverrisdottir A; Nystedt M; Johansson H; Fornander T
Breast Cancer Res Treat; 2009 Oct; 117(3):561-7. PubMed ID: 19153828
[TBL] [Abstract][Full Text] [Related]
50. Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.
Carlson RW; Theriault R; Schurman CM; Rivera E; Chung CT; Phan SC; Arun B; Dice K; Chiv VY; Green M; Valero V
J Clin Oncol; 2010 Sep; 28(25):3917-21. PubMed ID: 20679610
[TBL] [Abstract][Full Text] [Related]
51. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).
von Minckwitz G; Graf E; Geberth M; Eiermann W; Jonat W; Conrad B; Brunnert K; Gerber B; Vescia S; Wollert J; Kaufmann M
Eur J Cancer; 2006 Aug; 42(12):1780-8. PubMed ID: 16765589
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial.
; Castiglione-Gertsch M; O'Neill A; Price KN; Goldhirsch A; Coates AS; Colleoni M; Nasi ML; Bonetti M; Gelber RD
J Natl Cancer Inst; 2003 Dec; 95(24):1833-46. PubMed ID: 14679153
[TBL] [Abstract][Full Text] [Related]
53. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
54. Adjuvant hormonal therapy for premenopausal women with breast cancer.
Emens LA; Davidson NE
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
[TBL] [Abstract][Full Text] [Related]
55. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
Montagna E; Cancello G; Colleoni M
Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
[TBL] [Abstract][Full Text] [Related]
56. Selecting adjuvant endocrine therapy for breast cancer.
Eneman JD; Wood ME; Muss HB
Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
[TBL] [Abstract][Full Text] [Related]
57. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
Jonat W
Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
[TBL] [Abstract][Full Text] [Related]
58. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
59. [Adjuvant endocrine therapy in breast cancer].
Huober J; Thürlimann B
Ther Umsch; 2008 Apr; 65(4):193-200. PubMed ID: 18622910
[TBL] [Abstract][Full Text] [Related]
60. Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
Di Lauro L; Vici P; Del Medico P; Laudadio L; Tomao S; Giannarelli D; Pizzuti L; Sergi D; Barba M; Maugeri-Saccà M
Breast Cancer Res Treat; 2013 Aug; 141(1):119-23. PubMed ID: 23982884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
